The HPTN 083 clinical trial showed that a long-acting cabotegravir injection was superior to daily oral tenofovir/emtricitabine for HIV prevention among cisgender men and transgender women. The study found a 66% reduction in incident HIV infections in participants given cabotegravir compared to TDF/FTC.
A US study found that engaging disenfranchised men who have sex with men living with HIV in the US is possible, but achieving and maintaining viral suppression remains a challenge. Despite some progress, many participants still face personal, practical, and structural barriers to achieving success.
The HPTN 071 (PopART) study demonstrates a community-wide HIV prevention strategy can significantly reduce new HIV infections. Delivering in-home HIV testing with immediate referral to care and treatment led to a 30% decrease in new infections, outperforming another strategy offering universal treatment.
The HPTN 075 Study found an alarming rate of HIV infection among men who have sex with men (MSM) and transgender women (TGW) in sub-Saharan Africa. The incidence rate was substantially higher than the general population, indicating an urgent need for increased access to HIV prevention approaches.
The HPTN 074 study demonstrates a significant reduction in mortality and increased antiretroviral therapy usage among participants, leading to improved viral suppression. The integrated intervention combining psychosocial counseling and substance use treatment referrals was associated with enhanced uptake of these services.
The HPTN 084 study enrolls 3,200 HIV-uninfected women in seven countries to test the safety and efficacy of a long-acting injectable cabotegravir compared to daily oral TDF/FTC. The study aims to increase HIV prevention choices for women, particularly in sub-Saharan Africa where they bear a disproportionate burden.
The HPTN 077 study found that long-acting injectable cabotegravir was well-tolerated by men and women, with consistent levels in the bloodstream and good acceptance. The 600mg dose every 8 weeks showed promising results for HIV prevention.
The HPTN 065 study found that financial incentives can motivate some people living with HIV to take their medication regularly and maintain viral load suppression. This increase in viral suppression was observed at care sites offering financial incentives, with an overall increase of 5% at the peak of the intervention.
The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate the safety and effectiveness of injectable cabotegravir for PrEP in men who have sex with men and transgender women. The study aims to provide an alternative to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention.
The HPTN 073 study found that 79% of participants accepted PrEP, with 62% self-reporting high adherence and drug levels consistent with daily use. This suggests an effective strategy for preventing HIV infection among black MSM in the US.
The HPTN 052 study found that antiretroviral therapy (ART) provides durable protection against HIV transmission from infected individuals to their uninfected partners. The trial showed a 93% reduction in HIV transmission when ART was started early, with no observed transmission when viral replication was stably suppressed.
The AMP study aims to assess the safety and efficacy of VRC01 in reducing HIV-1 acquisition among at-risk populations. The randomized, double-blind trial will enroll 2700 participants and follow them for up to 72 weeks.
The HPTN 073 Study found that a novel coordinated counseling and care approach resulted in high uptake of PrEP among BMSM, suggesting a lower rate of HIV infection. The study showed that 92% of participants completed the 12-month follow-up and 79% accepted PrEP.
A Phase III trial found that conditional cash transfers for school attendance had no effect on reducing HIV incidence among high-school aged women in South Africa. However, these women reported fewer risk behaviors, such as fewer sex partners and less unprotected sex.
The HPTN 052 study demonstrates that early antiretroviral therapy significantly reduces HIV transmission in serodiscordant couples, with a sustained 93% reduction when the HIV-infected partner is on treatment and viral load suppressed. The trial also found that timely ART initiation can lead to improved health outcomes.
HPTN 067 study finds that high-risk populations in Bangkok, Harlem, and South Africa can adhere to daily PrEP regimens with high levels of coverage and satisfaction. The study suggests that non-daily dosing regimens could be a cost-effective alternative for increasing accessibility to PrEP.
Three studies show that becoming circumcised reduces a man's chances of acquiring HIV from an infected woman by approximately half. The Male Circumcision Consortium will work to expand voluntary male circumcision services in Kenya and other African countries, with the goal of saving millions of lives.